Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AETHER study of venetoclax plus epcoritamab in relapsed or refractory CLL/SLL
NL-OMON59097Phase 2Recruiting
- Sponsor
- HOVON
- Start
- May 2024
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epcoritamab and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by HOVON. Primary endpoints: Recommended phase II dose and Bone marrow uMRD4 after treatment. Started May 2024; status: recruiting.
02
Drugs
epcoritamabvenetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON59097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59097.